Carisma Therapeutics, Inc.

CARM

NASDAQ · Biotechnology

$0.00

At close - Oct 2, 4:00 PM EDT - USD

Market Cap$20923

P/E-0.0x

52W High$0.29

Volume916

VCP Research Verdict2025Q3

Clinical Development Costs Outpace Revenue Growth Trajectory

Carisma Therapeutics faces a precarious financial outlook as its reliance on lumpy, milestone-based revenue fails to offset the high costs of autologous cell therapy development. The company's rapid depletion of its cash reserves, which fell from $83.1 million...

GrowthMixed

ProfitabilityNegative

ValuationAttractive

TechnicalsWeak

Explore valuation models

MARKET ACTION

CARM price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Market performance

Price History →

Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

CARM-98.86%

S&P 500 (^GSPC)+12.66%

1-Year Return

CARM-99.81%

S&P 500 (^GSPC)+15.01%

3-Year Return

CARM-99.99%

S&P 500 (^GSPC)+80.11%

5-Year Return

CARM-97.56%

S&P 500 (^GSPC)+83.72%

Growth & profitability

Annual revenue & EPS trend

Revenue

$20M+31.6% YoY

Net income

-$60M+30.4% YoY

Free cash flow

-$60M+27.1% YoY

Operating margin

-316.7%+278.0 pts YoY

ROIC (TTM)-

Avg ROIC 5Y-

ROE (TTM)-

Piotroski Score4 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

MARKET COVERAGE

Latest News

1 Stories

Business Wire·Jul 29, 2026

Carmila: 2026 H1 Results

PARIS--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM): 2026 EPS1 guidance raised to €1.87 (from €1.84, vs €1.81 in 2025) Now expecting 3.3% EPS growth in 2026 Guidance upgrade driven by operating performance and Dijon Grand Quetigny acquisition Strong momentum across the three growth engines powered by asset transformation Organic growth: net rental income +1.4% (100 bps above indexation, continuing consistent outperformance) as restructuring and remerchandising have unlocked record ten.

Filtered for Carisma Therapeutics, Inc.More Headlines

Compare before deciding

Benchmark CARM against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Carisma Therapeutics, Inc. (CARM)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
CARMCarisma Therapeutics, Inc.Current	$0.00	$20.92K	-0.00	31.59%	-308.05%	—	—
MGTXMeiraGTx Holdings plc	$10.79	$999.26M	-7.60	144.57%	19.87%	283.85%	—
FATEFate Therapeutics, Inc.	$2.32	$270.42M	-2.02	-51.24%	-1941.09%	-65.08%	—
SANASana Biotechnology, Inc.	$2.89	$804.26M	-3.01	—	—	-134.49%	—
BEAMBeam Therapeutics Inc.	$24.50	$2.52B	-30.25	120.01%	-54.75%	-7.7%	—
NTLAIntellia Therapeutics, Inc.	$12.26	$1.38B	-3.22	16.92%	-672.16%	-57.79%	—

Compare CARM vs Peers

Carisma Therapeutics, Inc. (CARM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MGTX

Most directly comparable listed peer for CARM.

Scale Benchmark

vs ILMN

Larger-name benchmark to compare CARM against a more recognizable public peer.

Peer Set

Compare Top 5

vs MGTX, FATE, SANA, BEAM

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

CARM SEC Filings & Documents

Carisma Therapeutics, Inc. (CARM) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Dec 5, 2025·SEC

Material company update

Oct 15, 2025·SEC

Material company update

Oct 9, 2025·SEC

10-K Annual Reports

FY 2025

Mar 31, 2025·SEC

FY 2024

Apr 1, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 13, 2025·SEC

Get notified when CARM posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

CARM Frequently Asked Questions

Carisma Therapeutics, Inc. (CARM) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Carisma Therapeutics, Inc.'s revenue?

Carisma Therapeutics, Inc. (CARM) reported $52.6M in revenue for fiscal year 2024.

How fast is Carisma Therapeutics, Inc. growing?

Carisma Therapeutics, Inc. (CARM) grew revenue by 31.6% over the past year. This is strong growth.

Is CARM profitable?

Yes, Carisma Therapeutics, Inc. (CARM) is profitable, generating $8.0M in net income for fiscal year 2024 (-308.1% net margin).

Dividend & Returns

What is Carisma Therapeutics, Inc.'s free cash flow?

Carisma Therapeutics, Inc. (CARM) had negative free cash flow of $22.4M in fiscal year 2024, likely due to heavy capital investments.

What if you invested $1,000 in CARM back in 2011?

Total return calculator · dividends reinvested · 15+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

CARMCarisma Therapeutics, Inc.Current

$0.00

$20.92K

-0.00

31.59%

-308.05%

—

MGTXMeiraGTx Holdings plc

$10.79

$999.26M

-7.60

144.57%

19.87%

283.85%

—

FATEFate Therapeutics, Inc.

$2.32

$270.42M

-2.02

-51.24%

-1941.09%

-65.08%

—

SANASana Biotechnology, Inc.

$2.89

$804.26M

-3.01

—

-134.49%

—

BEAMBeam Therapeutics Inc.

$24.50

$2.52B

-30.25

120.01%

-54.75%

-7.7%

—

NTLAIntellia Therapeutics, Inc.

$12.26

$1.38B

-3.22

16.92%

-672.16%

-57.79%

—